Kamada (NASDAQ:KMDA – Get Free Report) and Biorestorative Therapies (NASDAQ:BRTX – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, earnings, dividends, risk, analyst recommendations and institutional ownership.
Earnings & Valuation
This table compares Kamada and Biorestorative Therapies”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Kamada | $180.46 million | 2.52 | $20.20 million | $0.38 | 20.84 |
| Biorestorative Therapies | $360,000.00 | 10.23 | -$14.24 million | ($1.07) | -2.50 |
Volatility & Risk
Kamada has a beta of 0.88, indicating that its share price is 12% less volatile than the S&P 500. Comparatively, Biorestorative Therapies has a beta of 0.83, indicating that its share price is 17% less volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of recent recommendations and price targets for Kamada and Biorestorative Therapies, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Kamada | 0 | 0 | 3 | 0 | 3.00 |
| Biorestorative Therapies | 1 | 0 | 0 | 0 | 1.00 |
Kamada presently has a consensus target price of $13.00, suggesting a potential upside of 64.14%. Given Kamada’s stronger consensus rating and higher possible upside, equities analysts clearly believe Kamada is more favorable than Biorestorative Therapies.
Insider & Institutional Ownership
20.4% of Kamada shares are held by institutional investors. Comparatively, 69.4% of Biorestorative Therapies shares are held by institutional investors. 36.1% of Kamada shares are held by insiders. Comparatively, 13.6% of Biorestorative Therapies shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Profitability
This table compares Kamada and Biorestorative Therapies’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Kamada | 11.60% | 8.37% | 5.85% |
| Biorestorative Therapies | -3,088.27% | -508.42% | -230.94% |
Summary
Kamada beats Biorestorative Therapies on 12 of the 14 factors compared between the two stocks.
About Kamada
Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite. The company also distributes imported drug products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX for hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.
About Biorestorative Therapies
BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. The company was incorporated in 1997 and is based in Melville, New York.
Receive News & Ratings for Kamada Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada and related companies with MarketBeat.com's FREE daily email newsletter.
